Skip to main content

Table 2 Patient characteristics

From: Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting

Age

Mean (SD)

61.6 (9.8)

 
  

N

%

Sex

Women

47

56.0%

Men

37

44.0%

Previous surgery

Yes

23

27.7%

No

60

72.3%

Missing

1

 

Previous radiotherapy

Yes

8

10.1%

No

71

89.9%

Missing

5

 

Regimens (1st line)

pemetrexed/cisplatin

34

40.5%

pemetrexed/carboplatin

28

33.3%

pemetrexed/ cisplatin (switch to pemetrexed/carboplatin)

9

10.7%

vinorelbine/carboplatin

7

8.3%

vinorelbine/cisplatin

2

2.4%

pemetrexed/carboplatin, (second vinorelbine/carboplatin)

2

2.4%

pemetrexed/carboplatin (reinduction with pemetrexed/cisplatin)

1

1.2%

pemetrexed/etoposid

1

1.2%

Cycles

1 cycle

3

3.6%

2 cycles

7

8.3%

3 cycles

12

14.3%

4 cycles

57

67.9%

5 cycles

2

2.4%

6 cycles

2

2.4%

8 cycles

1

1.2%

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us